Appointments from AAPS, SurModics, Diamedica, and Sirona Biochem – People on the move
The American Association of Pharmaceutical Scientists (AAPS) has elected Anthony DeStefano as its next executive council president-elect.
Currently, DeStefano is vice president of general chapters and acting documentary standards officer at the U.S. Pharmacopeial Convention (USP).
USP CEO Roger Williams said of the honour: “Dr. DeStefano has been justly rewarded for his expertise and dedication to advancing the quality of medicines, foods and supplements.”
SurModics has appointed three of its current staff to leadership positions as part of its reshuffle.
The drug delivery and pharmaceutical coating company has cut nine per cent of staff in an overhaul of their business strategy (see today’s article).
As part of the shake-up, senior director and general manager in vitro diagnostics Timothy Arens will become the new VP of finance and interim CFO.
Joseph Stitch, currently VP, marketing, corporate development and strategy will take on the leadership responsibilities for the in vitro diagnosis business.
And Bryan Phillips will assume the responsibilities of VP, Human Resources.
"This is a critical transition for SurModics to implement the components of our strategic plan that focus and position our business for maximum long-term success," said Gary Maharaj, President and Chief Executive Officer.
Drug and medical device maker Hospira has elected William Dempsey to its board of directors.
Dempsey joins the team after retiring from Abbott Laboratories in 2007, where he led the hospital products business.
"Bill understands how to successfully grow a large, multinational healthcare business," said Christopher B. Begley, executive chairman.
"His impressive track record of results-oriented leadership and operational experience in the healthcare field makes him an excellent fit for the Hospira board."
Stryker Corporation has named Ramesh Subrahmanian as its new group president, international.
Most recently as senior VP and president of Asia Pacific for Merck & Co, Subrahmanian boasts a career spanning 23 years in the pharmaceutical industry.
Chairman, president and CEO Stephen MacMillan said of the move: “Ramesh brings a strong global perspective to Stryker through his successful leadership roles in the U.S., Germany, India and Asia Pacific.
“He is a proven healthcare leader who has demonstrated the ability to drive profitable growth and innovation, and we look forward to taking advantage of his varied experiences as we continue to grow our international businesses.”
Ted Lithgow has joined the board of directors for Healthcare Compliance Packaging Council (HCPC).
Lithgow, currently the chief science officer of healthcare at MeadWestvaco, will be responsible for providing direction and identifying strategies to promote packaging as a way of improving patient compliance.
He said: "HCPC serves an important role as an advocate for improving patient adherence to medicines through packaging, and I am pleased to serve on HCPC's board with so many distinguished members of the adherence packaging community.
"I look forward to working more closely with HCPC and to contributing to the organization."
DiaMedica has expanded its scientific advisory board with the appointment of John Amatruda.
With over 150 scientific articles under his belt, Amatruda was also the senior VP and franchise head for diabetes and obesity at Merck Research Laboratories.
He led the development and regulatory approvals of Januvia and Janumet - the first compounds in the DPP-IV inhibitor class for Type 2 diabetes.
He said: "It is a pleasure to join the SAB of DiaMedica.
“DiaMedica has several approaches for the treatment of diabetes and I am excited to work with the company and its scientific advisors."
Bertrand Plouvier has become VP, product development at Sirona Biochem.
In his new role, Plouvier will be overseeing project management and development of Sirona Biochem's three programs in diabetes therapeutics, cosmeceuticals and biological ingredients.
He will take the helm on the Vancouver-based biotech’s biological assessment, as well as completing characterization of compounds from discovery through to preclinical proof of concept.
The American Association of Pharmaceutical Scientists (AAPS) has elected Anthony DeStefano as its next executive council president-elect.
Currently, DeStefano is vice president of general chapters and acting documentary standards officer at the U.S. Pharmacopeial Convention (USP).
USP CEO Roger Williams said of the honour: “Dr. DeStefano has been justly rewarded for his expertise and dedication to advancing the quality of medicines, foods and supplements.”
SurModics has appointed three of its current staff to leadership positions as part of its reshuffle.
The drug delivery and pharmaceutical coating company has cut nine per cent of staff in an overhaul of their business strategy (see today’s article).
As part of the shake-up, senior director and general manager in vitro diagnostics Timothy Arens will become the new VP of finance and interim CFO.
Joseph Stitch, currently VP, marketing, corporate development and strategy will take on the leadership responsibilities for the in vitro diagnosis business.
And Bryan Phillips will assume the responsibilities of VP, Human Resources.
"This is a critical transition for SurModics to implement the components of our strategic plan that focus and position our business for maximum long-term success," said Gary Maharaj, President and Chief Executive Officer.
Drug and medical device maker Hospira has elected William Dempsey to its board of directors.
Dempsey joins the team after retiring from Abbott Laboratories in 2007, where he led the hospital products business.
"Bill understands how to successfully grow a large, multinational healthcare business," said Christopher B. Begley, executive chairman.
"His impressive track record of results-oriented leadership and operational experience in the healthcare field makes him an excellent fit for the Hospira board."
Stryker Corporation has named Ramesh Subrahmanian as its new group president, international.
Most recently as senior VP and president of Asia Pacific for Merck & Co, Subrahmanian boasts a career spanning 23 years in the pharmaceutical industry.
Chairman, president and CEO Stephen MacMillan said of the move: “Ramesh brings a strong global perspective to Stryker through his successful leadership roles in the U.S., Germany, India and Asia Pacific.
“He is a proven healthcare leader who has demonstrated the ability to drive profitable growth and innovation, and we look forward to taking advantage of his varied experiences as we continue to grow our international businesses.”
Ted Lithgow has joined the board of directors for Healthcare Compliance Packaging Council (HCPC).
Lithgow, currently the chief science officer of healthcare at MeadWestvaco, will be responsible for providing direction and identifying strategies to promote packaging as a way of improving patient compliance.
He said: "HCPC serves an important role as an advocate for improving patient adherence to medicines through packaging, and I am pleased to serve on HCPC's board with so many distinguished members of the adherence packaging community.
"I look forward to working more closely with HCPC and to contributing to the organization."
DiaMedicahas expanded its scientific advisory board with the appointment of John Amatruda.
With over 150 scientific articles under his belt, Amatruda was also the senior VP and franchise head for diabetes and obesity at Merck Research Laboratories.
He led the development and regulatory approvals of Januvia and Janumet - the first compounds in the DPP-IV inhibitor class for Type 2 diabetes.
He said: "It is a pleasure to join the SAB of DiaMedica.
“DiaMedica has several approaches for the treatment of diabetes and I am excited to work with the company and its scientific advisors."
Bertrand Plouvier has become VP, product development at Sirona Biochem.
In his new role, Plouvier will be overseeing project management and development of Sirona Biochem's three programs in diabetes therapeutics, cosmeceuticals and biological ingredients.
He will take the helm on the Vancouver-based biotech’s biological assessment, as well as completing characterization of compounds from discovery through to preclinical proof of concept.
